Genetic or pharmacological inhibition of NRP1 in glioma TAMs reprograms them towards an antitumor phenotype, by reducing angiogenesis and enhancing lymphocyte infiltration, thus delaying tumor progression [40,41]. The gene discussed is NRP1; the disease is central nervous system cancer.